Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-ESIDRIX #2 vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension
Hypertension
1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Reserpine: 50-100 hours (biphasic; terminal phase 11-16 days due to slow release from adrenergic storage sites); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Reserpine is extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces. Hydrochlorothiazide is not metabolized extensively; it is primarily eliminated unchanged by the kidneys.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Reserpine: 60% renal (as metabolites), 40% fecal (as parent drug and metabolites); Hydrochlorothiazide: >95% renal (unchanged) via tubular secretion.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Reserpine: 96% bound to albumin; Hydrochlorothiazide: 40-68% bound to albumin.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Reserpine: 5-8 L/kg (extensive tissue binding, particularly to adrenergic neurons); Hydrochlorothiazide: 0.83-1.14 L/kg (distributes into extracellular fluid).
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Reserpine: 50-60% (oral, extensive first-pass metabolism); Hydrochlorothiazide: 65-75% (oral, with food decreasing absorption by 10-20%).
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
Contraindicated if GFR < 30 m L/min. For GFR 30-59 m L/min, maximum dose is 1 tablet every other day due to hydrochlorothiazide accumulation.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: caution, consider reducing dose. Child-Pugh B: contraindicated due to risk of hepatic coma and reserpine-induced depression. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not recommended for children. Safety and efficacy not established.
Not established; avoid use in children.
Initiate with 0.5 tablet once daily due to increased sensitivity to reserpine (CNS depression) and hydrochlorothiazide (hypotension, electrolyte imbalance). Titrate slowly.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
Reserpine may cause depression, and should be discontinued if symptoms occur; use with caution in patients with history of depression.,Hydrochlorothiazide may cause electrolyte imbalances (e.g., hypokalemia), dehydration, and increased serum uric acid and glucose.,May cause orthostatic hypotension, especially with alcohol or other antihypertensives.,Renal impairment: monitor renal function.,Hepatic impairment: use with caution as reserpine may precipitate hepatic encephalopathy.,Sulfonamide allergy: hydrochlorothiazide is a sulfonamide derivative; cross-sensitivity may occur.,May require dosage adjustment in renal impairment.,Avoid abrupt discontinuation of reserpine; taper gradually.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to reserpine, hydrochlorothiazide, or sulfonamides.,History of mental depression or suicidal tendencies.,Active peptic ulcer or ulcerative colitis.,Electroconvulsive therapy (ECT) within 7 days.,Anuria or severe renal impairment (e.g., creatinine clearance <30 m L/min).,Pheochromocytoma (reserpine may paradoxically increase blood pressure).
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
High-potassium foods (bananas, oranges, spinach) may increase risk of hyperkalemia if used with potassium-sparing diuretics; however, hydrochlorothiazide is potassium-wasting, so hypokalemia risk exists. Avoid excessive sodium intake (processed foods, salt) as it can reduce antihypertensive effect. Grapefruit juice may interact with reserpine; limit consumption.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
Serpasil (reserpine) is classified as FDA Pregnancy Category C. Reserpine crosses the placenta. First trimester: Limited human data, but animal studies suggest increased risk of skeletal and cardiovascular anomalies. Second and third trimesters: Possible adverse effects including neonatal respiratory depression, bradycardia, hypothermia, and hypotonia. Esidrix (hydrochlorothiazide) is FDA Pregnancy Category B; however, thiazide diuretics may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use only if clearly needed.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Reserpine is excreted into breast milk; M/P ratio not established. Potential for severe adverse effects in nursing infants including respiratory depression, bradycardia, and hypotonia. Hydrochlorothiazide is excreted in breast milk in low amounts (M/P ratio approximately 0.4-0.5), but may suppress lactation and cause electrolyte disturbances. Avoid breastfeeding during therapy.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Pregnancy can increase volume of distribution and renal clearance, potentially reducing drug concentrations. No specific dose adjustment studies for Serpasil-Esidrix #2; however, based on components: Hydrochlorothiazide may require increased dose due to enhanced clearance, but use lowest effective dose. Reserpine dosing should be minimized due to fetal risks. Avoid use in pregnancy if possible; alternative antihypertensives recommended.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Serpasil (reserpine) plus Esidrix (hydrochlorothiazide) #2 is a fixed-dose combination for hypertension. Reserpine depletes catecholamines: monitor for depression, nasal congestion, sedation, and bradycardia. Hydrochlorothiazide: check electrolytes, uric acid, glucose; avoid in anuria. Onset of reserpine action is slow (weeks) but prolonged (weeks after discontinuation). Combination may exacerbate gout and diabetes.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not stop suddenly as high blood pressure may worsen.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until effects are known.,Avoid alcohol as it can increase dizziness and drowsiness.,Report symptoms of depression, slow heart rate, severe nasal congestion, or unusual bleeding/bruising.,Use sun protection as hydrochlorothiazide increases sun sensitivity.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst.,Inform all healthcare providers you are taking this medication, especially before surgery.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-ESIDRIX #2 vs ALDORIL 25, answered by our medical review team.
SERPASIL-ESIDRIX #2 is a Antihypertensive Combination that works by Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-ESIDRIX #2 and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-ESIDRIX #2 is: 1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-ESIDRIX #2 and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-ESIDRIX #2 is classified as Category C. Serpasil (reserpine) is classified as FDA Pregnancy Category C. Reserpine crosses the placenta. First trimester: Limited human data, but animal studies suggest increased risk of sk. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.